Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatch and ring take on the 12-Lead ECG in heart rhythm showdown

NCT ID NCT05298553

Diagnosis Sponsor: Oxford University Hospitals NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether two wearable devices—the Apple Watch and the Skylab CART-I ring—can accurately detect atrial fibrillation and other irregular heart rhythms compared to the standard 12-lead ECG. Researchers recruited 500 adults from UK cardiology clinics. Each participant wore both devices and had their heart rhythm recorded simultaneously with the standard test. The goal was to see if the wearables' single-lead ECGs and automatic detection algorithms could match the gold standard. If successful, these devices could make it easier to spot hidden heart rhythm problems without a clinic visit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Apple Watch and Skylab CART-I ring (wearable single-lead ECG devices)
What this could lead to
If these wearables prove accurate, they could help catch hidden heart rhythm problems earlier, potentially preventing strokes.
What could go wrong
This is a completed diagnostic study, not a treatment trial. The devices may not be as reliable as the gold-standard 12-lead ECG, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

500 people

The number who actually took part.

Started

Apr 2022

Finished

Apr 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the trial. * Male or female aged 18 years or above. * Indication for 12-lead ECG. Exclusion Criteria: * Unable to comply with instructions. * Tattoos in the wrists or fingers where the device will be placed. * Severe skin allergy to silicone (Apple Watch wrist band) or nickel allergies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Cardiac arrhythmia

Contacts and locations

Locations

  • Oxford Univeristy Hospitals NHS Foundation Trust

    Oxford, Oxfordshire, OX89DU, United Kingdom

  • University Hospital Birmingham

    Birmingham, United Kingdom

  • University Hospital Southampton

    Southampton, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.